Back to top

Image: Bigstock

Encompass Health Stock Rallies 34% YTD: Is There More Upside Ahead?

Read MoreHide Full Article

Key Takeaways

  • EHC's 33.9% YTD gain tops the industry's 32% and the S&P 500's 9.4%, while analysts target $156.08.
  • EHC's third-quarter revenue rose 8.9%, adjusted EBITDA gained 15.5%, and patient discharges climbed 5.7%.
  • EHC plans eight new hospitals in 2026, but rising costs and reimbursement pressures could test margins.

Encompass Health Corporation (EHC - Free Report) has soared  33.9% year to date, edging past the industry’s 32% gain and comfortably beating the S&P 500’s 9.4% rise. Consistent operating growth, improving profitability outlook, strategic capacity expansion and shareholder-friendly initiatives have helped keep buyers interested. 

Trading at $142.11, EHC is close to the 52-week high of $143.90 reached last week. Wall Street’s average price target of $156.08 suggests further upside, but the recent run also raises a fair question: Is there enough room left for new investors?

EHC YTD Share Price Performance Vs. Industry & S&P 500

Zacks Investment Research Image Source: Zacks Investment Research

EHC’s Growth Drivers

An aging population and greater need for rehabilitation care continue to support hospital admissions. Encompass Health is converting that demand into stronger results while keeping expenses in check. Third-quarter 2026 revenues rose 8.9% to $1.61 billion, and adjusted EBITDA grew 15.5% to $346.6 million. Adjusted earnings increased 23.6% to $1.52 per share. Patient discharges advanced 5.7%, including 3% growth at existing hospitals. Growth at existing sites shows that demand is not limited to newly opened hospitals.

The company is also building capacity to handle more patients. In the first nine months of 2026, it opened four hospitals with a combined 189 beds and added 85 beds at existing locations. Its full-year plan calls for eight new hospitals offering 389 beds, plus 145-190 additional beds across current facilities.

Capital returns add another layer of support. After repurchasing $203.7 million of shares during the first nine months, EHC had about $955 million remaining under its expanded $1 billion buyback authorization as of September-end. The company also paid $57.9 million in dividends over the same period.

Rising Estimates Add to the Case

Reflecting the positive sentiment around Encompass Health, the Zacks Consensus Estimate for earnings per share has seen six upward revisions over the past month and no downward changes. The consensus estimate for 2026 adjusted earnings for EHC is currently pegged at $6.23 per share, which indicates 14.3% year-over-year growth. The consensus mark for 2027 suggests a further 8.6% jump.

The company beat earnings estimates in each of the past four quarters, with an average surprise of 8.5%. The consensus estimate for 2026 and 2027 revenues suggests 9.1% and 8.3% year-over-year growth, respectively.

Key Concerns for EHC

There are a few factors that investors should keep an eye on.

Encompass Health remains exposed to reimbursement pressures and increasing labor expenses. Management expects Medicare pricing to increase approximately 2.3% in the fourth quarter of 2026, while salaries and benefits per full-time equivalent employee are projected to rise 3.5-4%.

Additionally, bad-debt reserves increased to 2.7% of revenues in the third quarter from 1.9% a year earlier, reflecting billing and collection disruptions following a system conversion. Persistent cost inflation, reimbursement constraints and collection challenges could impact future margin expansion.

Final Verdict: Buy EHC Stock Now

Encompass Health’s strong patient volumes, expanding hospital network and rising earnings estimates point to continued momentum. Healthy cash generation and shareholder returns add to its appeal. While reimbursement and labor costs remain challenges, its strong operating performance supports further stock price upside. EHC currently carries a Zacks Rank #2 (Buy).

Other Key Picks

Investors can look at some other top-ranked stocks in the broader Medical space, like The Ensign Group, Inc. (ENSG - Free Report) , Pediatrix Medical Group, Inc. (MD - Free Report) and Chemed Corporation (CHE - Free Report) . Each stock currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Ensign’s 2026 bottom line suggests 21.2% year-over-year growth. ENSG witnessed two upward estimate revisions over the past month against no movement in the opposite direction. It beat earnings estimates in each of the last four quarters, with the average surprise being 4.7%.

The Zacks Consensus Estimate for Pediatrix Medical’s 2026 bottom line is pegged at $2.39 per share, which indicates 17.2% growth from a year ago. During the past month, MD witnessed three upward estimate revisions against none in the opposite direction. It beat earnings estimates in three of the last four quarters and missed once, with the average surprise being 9.5%.

The Zacks Consensus Estimate for Chemed’s current-year earnings implies a 19.6% increase from the year-ago reported figure. CHE beat earnings estimates in three of the last four quarters and missed once, with an average surprise of 3.9%. The consensus mark for its current-year revenues is pegged at $2.73 billion, which indicates an 8% year-over-year increase.

Published in